Italia markets closed

Calliditas Therapeutics AB (publ) (0A5R.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a watchlist
113,44-1,36 (-1,19%)
Alla chiusura: 05:54PM GMT

Calliditas Therapeutics AB (publ)

Kungsbron 1, D5
Stockholm 111 22
Sweden
46 84 11 30 05
https://www.calliditas.se

Settore/i
Settore
Impiegati a tempo pieno192

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Ms. Renee Aguiar-LucanderChief Executive Officer8,99MN/D1962
Mr. Fredrik JohanssonChief Financial OfficerN/DN/D1977
Dr. Johan Haggblad Ph.D.Chief Scientific Officer1,66MN/D1958
Mr. Brian GormanGroup General CounselN/DN/D1976
Ms. Sandra FrithiofHead of Human ResourcesN/DN/D1975
Ms. Ann-Kristin Myde BScHead of Clinical Development & VP of Project ManagementN/DN/D1955
Dr. Krassimir MitchevHead of Medical AffairsN/DN/D1959
Dr. Richard S. Philipson M.D.Chief Medical OfficerN/DN/D1964
Ms. Teona JohnsonHead of US MarketingN/DN/DN/D
Mr. David FerraroHead of US SalesN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Calliditas Therapeutics AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.